Observational analysis identifies new CaSR agonists in vitro, suggesting potential alternatives to calcimimetics.
Human calcium-sensing receptor (CaSR) is a class C G protein–coupled receptor (GPCR) that directly regulates parathyroid hormone release and maintains calcium homeostasis. The discovery of potent CaSR agonists with computer-aided drug design (CADD) has been appealing. Herein, we report the discovery of a series of new CaSR agonists by enhancing the molecular binding affinity through the replacement of key residues via the iCVETide platform. Ac-D-Cys(L-Cys)-D-Arg-D-(3-Gu)-Phe-D-Abu-D-Arg-D-Ala-D-Arg-NH2 (compound 6g) with an outstanding activity and a satisfactory ADME profile is discovered, and the interaction mode between 6g and CaSR is elucidated through molecular docking and molecular dynamics simulations, showing hydrogen bonds, salt bridges, and π–π stacking. In addition, 6g is capable of activating human CaSR as a calcimimetic positive allosteric modulator. Our results provide a viable alternative to approved calcimimetics and a novel protocol for the discovery of CaSR agonists.
No takes yet. Share an insight, caveat, or question.
Yuan et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: